



Center for Vaccine Ethics & Policy (CVEP)
Vaccines and Global Health: The Week in Review
05 September 2026 :: Issue 859

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director, Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

Mpox Vaccines Stockpile

Global initiative launched to improve access to mpox vaccines

GENEVA/NEW YORK/COPENHAGEN, 2 September 2026 – **A global initiative to establish a stockpile of mpox vaccines was launched on 27 August, creating a long-term mechanism to ensure countries have access to vaccines when responding to mpox outbreaks.**

Set to begin operations later this month, this new global mpox vaccine stockpile that all countries can access is a resource that was **approved by the Board of Gavi, the Vaccine Alliance (Gavi) in 2025, and is funded by Gavi and coordinated by the International Coordinating Group (ICG) on Vaccine Provision.**

The ICG partners are the International Federation of Red Cross and Red Crescent Societies (IFRC), Médecins Sans Frontières (MSF), the United Nations Children’s Fund (UNICEF) and the World Health Organization (WHO).

The initiative builds on the Access and Allocation Mechanism established in 2024 during the last mpox Public Health Emergency of International Concern (PHEIC), and will ensure that countries have timely and equitable access to vaccines for outbreak response.

Mpox continues to cause outbreaks globally, with two-thirds of reported cases occurring in the African Region. From 1 January 2022 to 31 July 2026, 145 countries and territories reported 190 683 confirmed cases and 529 deaths...

Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said: “The launch of a stockpile of mpox vaccines is an important step towards a more sustainable and equitable approach to mpox outbreak response. By establishing a dedicated global stockpile, using an approach that has proven successful for managing other emergency vaccines, we are ensuring that countries can access them more quickly when they need them, saving lives and containing outbreaks before they spread further.”

.....
.....

Rare Diseases

Global action plan on rare diseases – process and next steps

31 August 2026 *Departmental update*

Rare diseases affect millions of people globally and are often complex, involving multiple organ groups and resulting in disabilities and premature death. Many people living with a rare disease frequently experience diagnostic delays, fragmented care, limited access to effective interventions, financial hardship, stigma and social exclusion.

World Health Assembly resolution WHA78.11 (2025) *Rare diseases: a global health priority for equity and inclusion* requests the Director-General to develop, in consultation with Member States and relevant stakeholders, **a comprehensive 10-year global action plan on rare diseases with**

strategic objectives, global targets and an accountability and monitoring framework for consideration by the Eighty-first World Health Assembly in 2028.

Consultative process

The Secretariat will follow the below consultative process to facilitate the preparation of the draft action plan:

- Information on the process to develop the global action plan on rare diseases will be provided to Member States.
- The Secretariat will publish online a discussion paper on the global action plan on rare diseases in the last quarter of 2026. Member States, United Nations (UN) agencies and relevant non-State actors, including organizations representing people with lived experience, will be invited to provide their inputs on the discussion paper through a web-based platform.
- Based on feedback on the content of the discussion paper, the first draft of the Global action plan on rare diseases will be developed in early 2027. Web-based and virtual informal consultations will then be carried out to seek comments from Member States, UN agencies and relevant non-State actors including people living with rare diseases and their carers and families. The consolidated comments received on the first draft will subsequently be published online.
- The outcomes of the informal consultations on the first draft will serve as inputs for the WHO Secretariat to prepare a revised draft which will be submitted for review to the WHO Executive Board in 2028 (162nd session) for consideration at the Eighty-first World Health Assembly in May 2028.

.....
.....
.....

Ebola – Bundibugyo virus disease (BVD) – PHEIC/PHECS

WHO

1 September 2026

[WHO emergency guidance on the use of licensed Ebola vaccine during Bundibugyo virus disease outbreaks,...](#)

31 August 2026

Overview

This updated WHO emergency guidance provides recommendations on the potential use of Ervebo®, the only licensed Ebola vaccine, during outbreaks caused by Bundibugyo virus (BDBV). The document reviews additional animal, immunological and observational evidence assessed by the Strategic Advisory Group of Experts on Immunization (SAGE) and concludes that, although some findings suggest possible cross-protection against BDBV, the available evidence remains insufficient to determine whether Ervebo® provides clinically meaningful protection in humans.

The guidance outlines the benefits, risks and unknowns associated with off-label use of Ervebo® during the ongoing BDBV outbreak and recommends that the vaccine be used only within research protocols. It emphasizes the importance of rapidly generating robust efficacy data through a ring randomized controlled trial, maintaining proven outbreak-control measures, clearly communicating the unknown efficacy against BDBV, and accelerating development of BDBV-specific vaccines and other countermeasures.

.....

Africa

[Ten Africa countries sign agreement to strengthens cross-border cooperation for health emergencies](#)

3 September 2026 | *News releases*

Addis Ababa—Ministers of Health from 10 African countries have signed a Cross-Border Collaboration Memorandum of Understanding (MoU) to strengthen coordination, information-sharing and joint preparedness and response to public health emergencies across borders. The agreement provides a framework for countries to work together before, during and after emergencies, strengthen early detection and response, clarify roles and responsibilities, and support coordinated action along high-risk border areas.

The signing of the Cross-Border Collaboration MoU and the announcement of the global mpox vaccine stockpile took place during a high-level side event on the margins of the 76th Session of the WHO Regional Committee for Africa (RC76) on 27 August 2026 in Addis Ababa. Convened by the WHO Regional Office for Africa (WHO AFRO), the World Bank, Africa CDC and Gavi, the event was held under the theme, "Strengthening Cross-Border All-Hazards Preparedness and Response in Africa: From Fragmented Actions to Collective Resilience."

"Strengthening cross-border collaboration is essential to protecting populations from public health emergencies," said Dr Mohamed Janabi, WHO Regional Director for Africa. "Countries need to work together before emergencies occur, ensuring that the systems, capacities and partnerships in place to support timely detection and effective response."...

::::::

INGOs

No new digest content identified.

::::::

::::::

::::::

Polio – PHEIC

[Polio this week](#) [26 Aug 2026]

Headlines [Selected]

:: High-level polio delegation visits Chad as President Déby is named champion for polio eradication and immunization

A high-level delegation of global polio and immunization partners met with Chadian authorities this week, including President Mahamat Idriss Déby Itno, to advance political commitment and regional cooperation for polio eradication and stronger immunization in Chad and across the Lake Chad Basin. The visit was marked by the designation of President Déby as Regional Champion for Polio Eradication and Immunization in the Lake Chad Basin, recognizing Chad's important role in driving collective action across the region. In this role, President Déby will help keep polio eradication and immunization high on the regional agenda, promote stronger cooperation among countries and advocate for sustained action to reach every child, including those living in border areas and among mobile, displaced and underserved communities.

African Health Ministers adopt framework to safeguard Africa's polio gains

African ministers of health and high-level representatives last week adopted a ten-year plan to sustain polio eradication efforts by strengthening national health systems and reaffirmed commitment to protect decades of investment towards a polio-free continent. The Framework for Polio Transition and Sustainability in the World Health Organization (WHO) African Region 2026–2035 was adopted during the Seventy-sixth session of the WHO Regional Committee for Africa, held in Addis Ababa, Ethiopia, from 25–28 August 2026. [More](#).

SAGE Polio Working Group advocates for increased IPV use in high-risk and outbreak settings

Last week, the Strategic Advisory Group of Experts on immunization (SAGE) Polio Working Group convened to take stock of progress toward eradication and to examine additional strategy interventions to help accelerate and sustain eradication. Discussions in particular focused on adding a third dose of inactivated polio vaccine (IPV) to routine immunization schedules in high-risk countries, and a second dose of fractional IPV (fIPV) for outbreak response in those instances when circulation continues beyond six months, despite multiple vaccination campaigns. Experience from key outbreak countries suggests adding the second fIPV dose to OPV response significantly accelerates the stopping of outbreaks.

Summary of new polioviruses this week:

- :: Pakistan: six WPV1-positive environmental samples
- :: DR Congo : eight cVDPV2 cases
- :: Mali : one cVDPV2 case
- :: Nigeria : two cVDPV3 cases
- :: South Sudan : one cVDPV1 case and three cVDPV2 cases

.....
.....

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

.....
.....

WHO & Regional Offices [05 Sep 2026]

<https://www.who.int/news>

Selected News/Announcements/Statements

4 September 2026 *News release*

[WHO validates Bhutan for eliminating dog-transmitted human rabies](#)

4 September 2026 *Departmental update*

[WHO advances access to quality-assured, child-friendly cancer medicines](#)

3 September 2026 *News release*

[WHO validates Timor-Leste's elimination of trachoma as a public health problem](#)

2 September 2026 *Joint News Release*

[Global initiative launched to improve access to mpox vaccines](#)

2 September 2026 *Departmental update*

[The Third Global Summit on Traditional Medicine set for November 2027](#)

1 September 2026 *Departmental update*

WHO moves to expand access to lifesaving sickle cell treatment and care for children

31 August 2026 *Departmental update*

Global action plan on rare diseases – process and next steps

31 August 2026 *Departmental update*

African Traditional Medicine Day 2026: from research to reach, advancing health for all

.....

WHO Vaccines and Immunization [IVB]

https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1

News

4 September 2026 *News release*

WHO validates Bhutan for eliminating dog-transmitted human rabies

2 September 2026 *Joint News Release*

Global initiative launched to improve access to mpox vaccines

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 3 September 2026 | *Feature Stories*

Community dialogue building trust in Ebola response in the Democratic Republic of the Congo

:: 3 September 2026 | *News releases*

Ten Africa countries sign agreement to strengthen cross-border cooperation for health emergencies

:: 2 September 2026 | *Feature Stories*

On the frontlines of infection prevention for Ebola control

WHO Region of the Americas PAHO

:: 3 Sep 2026

New tool will help countries in Latin America and the Caribbean prevent rabies and other zoonotic diseases through better data on dog and cat populations

The methodology provides a practical and adaptable approach to estimating dog and cat populations, improving the planning of vaccination campaigns, disease surveillance, and other public health interventions. Rio de Janeiro, September 3, 2026 (PANAFTOSA/VPH-PAHO/WHO) – The Pan American Center for Foot-and-Mouth Disease and Veterinary Public Health...

:: 1 Sep 2026

Maternal vaccination protects mothers and newborns, but coverage gaps persist across the Americas

Experts highlighted the importance of strengthening maternal vaccination efforts, including through routine recommendations during prenatal care, to better protect pregnant women and their babies.

US Proposal to Eliminate PAHO Funding Raises Alarm Over Health Security in Americas

Health Policy Watch, 03/09/2026 Sophia Samantaroy

... Amid ongoing outbreaks across the Americas, the US President's Fiscal Year 2027 budget request to Congress proposes eliminating funding to PAHO, calling it and the World Health Organization (WHO) "corrupt organizations" that show "no independence from inappropriate political influence", part of a raft of international organisations it describes as promoting "dangerous ideologies" and "taking advantage of American generosity".

The US is the largest single contributor to PAHO and accounts for half of all member state contributions to the organization. The US already owes nearly \$135 million in member fees since 2024...

WHO South-East Asia Region SEARO

:: **WHO validates Bhutan for eliminating dog-transmitted human rabies**

4 September 2026 | *News release*

:: **WHO validates Timor-Leste's elimination of trachoma as a public health problem**

3 September 2026 | *News release*

:: **Thailand verified for eliminating rubella as a public health problem**

5 September 2026 | *News release*

WHO European Region EURO

:: 4 September 2026 *Media release*

Ukraine: 3 WHO humanitarian warehouses destroyed in 3 months

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health
No new digest content identified.

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

4 September 2026, Vol. 101, No. 35

https://hq_weeklyepidemiologicalrecord.cmail19.com/t/d-l-wyuwud-ijjdtklujh-y/

:: Highlighted Signals and Events

:: Global Respiratory Virus Activity: Weekly Update
:: Multi-country outbreak of cholera

::::::

New WHO Publications

<https://www.who.int/publications>

Selected

3 September 2026

Vaccines, thiomersal and autism spectrum disorder: evidence review 2010-2025

Overview

This systematic review provides a current assessment of peer-reviewed studies published between 2010 and August 2025 investigating potential associations between vaccines and autism spectrum disorder (ASD), with particular focus on the organomercury vaccine component thiomersal, and also considers studies reporting other neurodevelopmental disorders (NDD). It updates previous WHO reviews by assessing the methodological quality, strength of evidence and risk of bias of the available literature. The review finds that the most methodologically rigorous primary studies do not support a causal association between vaccines, including thiomersal-containing vaccines, and ASD. Studies reporting positive associations had very low strength of evidence and high risk of bias, while none of the included meta-analyses supported a causal relationship. Overall, the evidence continues to support the safety of current vaccines with respect to ASD and other NDD. The review aims to provide clinicians, policy-makers and public health professionals with reliable and balanced evidence to inform decision-making, strengthen vaccine confidence and contextualize ongoing scientific and public dialogue.

2 September 2026

Integration of equity into national action plans on antimicrobial resistance: guidance to complement the people-centred approach

1 September 2026

WHO emergency guidance on the use of licensed Ebola vaccine during Bundibugyo virus disease outbreaks,...

31 August 2026

Overview

This updated WHO emergency guidance provides recommendations on the potential use of Ervebo®, the only licensed Ebola vaccine, during outbreaks caused by Bundibugyo virus (BDBV). The document reviews additional animal, immunological and observational evidence assessed by the Strategic Advisory Group of Experts on Immunization (SAGE) and concludes that, although some findings suggest possible cross-protection against BDBV, the available evidence remains insufficient to determine whether Ervebo® provides clinically meaningful protection in humans.

The guidance outlines the benefits, risks and unknowns associated with off-label use of Ervebo® during the ongoing BDBV outbreak and recommends that the vaccine be used only within research protocols. It emphasizes the importance of rapidly generating robust efficacy data through a ring randomized controlled trial, maintaining proven outbreak-control measures, clearly communicating the unknown efficacy against BDBV, and accelerating development of BDBV-specific vaccines and other countermeasures.

Urban yellow fever risk management: handbook for national preparedness and response planning

31 August 2026 | Handbook

Overview

This handbook provides practical guidance to help countries prepare for and respond to the risk of urban yellow fever outbreaks. It highlights that even a single yellow fever case in an urban setting can signal a potential public health emergency where *Aedes aegypti* mosquitoes are present and population immunity is low. The handbook supports early detection, rapid response and coordinated preparedness efforts, helping countries assess and manage urban yellow fever risk and develop context-specific contingency plans.

Organized around seven preparedness and response pillars, the handbook offers operational tools, checklists and scenario-based actions for coordination, surveillance, laboratory testing, community engagement, clinical care, vaccination, vector control, and management of travel and population movement. It enables Member States to identify gaps, strengthen capacities and implement measures to prevent urban transmission, reduce illness and deaths, and protect vulnerable populations.

.....
.....
.....

Africa

Africa CDC [05 Sep 2026]

<https://africacdc.org/>

News & Updates [Selected]

Press Release

[Africa CDC Selected to Represent Regional Health Organizations Worldwide on Global Health Architecture Reform Task Force](#)

Africa CDC will bring the priorities of its 55 African Union Member States and the perspectives of regional health organizations into the global reform process

Addis Ababa, Ethiopia, 31 August 2026 – The Africa Centres for Disease Control and Prevention (Africa CDC) has been selected to represent regional health organizations worldwide on the Joint Task Force on Global Health Architecture Reform.

Following nominations from several regional health organizations, the World Health Organization formally invited H.E. Dr Jean Kaseya, Director General of Africa CDC, to join the Task Force as their representative.

"We receive this recognition with humility and with a clear understanding of the responsibility it carries," said Dr Kaseya. "Our first responsibility is to bring forward the priorities and perspectives of our 55 African Union Member States, while engaging other regional institutions to ensure that their voices are heard."

The Joint Task Force is part of the Member State-led process to reform the global health architecture, following the decision of the Seventy-ninth World Health Assembly and the UN80 Initiative. It will develop options and recommendations for consideration by the Eightieth World Health Assembly, focusing on the functions, mandates and capacities of global health actors; coordination and decision-making; and the financing of global health priorities.

African Medicines Agency [05 Sep 2026]

<https://au-ama.africa/news-events/>

Latest News & Events

No new digest content identified.

.....
.....

China – CDC+

National Health Commission of the People's Republic of China [05 Sep 2026]

<http://en.nhc.gov.cn/>

News

Website not responding at inquiry.

National Medical Products Administration – PRC [05 Sep 2026]

<http://english.nmpa.gov.cn/>

Website not responding at inquiry.

China CDC

CCDC Weekly Reports: Current Volume (8)

<https://weekly.chinacdc.cn/article/current>

2026 Vol. 8 No. 36 [PDF](#)

No new digest content identified.

.....

.....

Europe

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

[Communicable disease threats report, 29 August - 4 September, week 36](#)

4 September 2026

Surveillance and monitoring

[Seasonal surveillance of dengue in the EU/EEA](#)

4 September 2026

Surveillance and monitoring

[Seasonal surveillance for chikungunya virus disease in the EU/EEA for 2026](#)

4 September 2026

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[Executive Director's speech at Duke-NUS Medical School in Singapore](#)

Emer Cooke spoke about reimagining the future of medicines regulation as part of the Sir Alasdair Breckenridge Lecture Series

4 September 2026

[Voluntary data submission pilot to advance innovative alternatives to animal testing](#)

Developers can submit New Approach Methodologies (NAMs) data and receive tailored feedback.

1 September 2026

.....

.....

India

National Centre for Disease Control

Directorate General of Health Services, Ministry of Health & Family Welfare

Announcements

No new digest content identified.

Indian Council of Medical Research (ICMR)

Press Releases

No new digest content identified.

.....
.....
.....

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, either boxing or indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive

Executive Branch - White House, State, HHS, FDA, CDC+ White House

Presidential Actions – Executive Orders; Memoranda; Proclamations

No new digest content identified.

Department of State

Press Releases - Selected

No new digest content identified.

Trump admin to 'radically' cut health aid in 18 countries, report says

Public Citizen and Partners In Health found that the Trump administration is planning a 59% reduction in health spending in 18 countries by 2030 — about \$2 billion.

Devex, by Sara Jerving 01 September 2026

The Trump administration is planning a 59% cut in U.S. health spending to 18 countries by 2030 — a reduction of about \$2 billion compared to funding levels before President Donald Trump returned to office, according to a new analysis by Public Citizen and Partners In Health that examines U.S. bilateral health deals with countries the organizations were able to access. ...

The new analysis examines 18 multiyear memorandums of understanding that are currently available, including those obtained through the lawsuit. It found that by the final year of implementation, U.S. government funding would fall by between 43% and 97% in the countries covered by the agreements. Rwanda faces the steepest reduction, at 97% compared to pre-2025 levels. ...

Peter Maybarduk, access to medicines director for Public Citizen, wrote in a press release that “the administration must answer how and when it intends to invest the missing billions for health.”

HHS

Press Room - Selected

No new digest content identified.

NIH [to 05 Sep 2026]

News Releases

Physician-scientist and informatics leader Dr. Peter Embí to helm NIH's National Library of Medicine

September 2, 2026 — He is anticipated to begin his role on Sept. 10, 2026.

FDA

Press Announcements

No new digest content identified.

FDA CBER

What's New for Biologics

09/02/2026 [SOPP 8203: Administrative Processing and Review Management of Charging Requests \(Cost Recovery Requests\) for Investigational New Drugs and Investigational Devices](#)

09/02/2026 [August 19, 2026 Summary Basis for Regulatory Action - GENGLYCOS](#)

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]

Advisory Committee Calendar

No future meeting dates posted.

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar

Pediatric Advisory Committee Meeting Announcement - 09/16/2026

CDC

<http://www.cdc.gov/media/index.html>

Latest News - Selected

No new digest content identified.

CDC – Immunization Safety Office (ISO)

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

No new digest content identified [last updated August 7, 2024]

ACIP

2026 Meetings Schedule *[as posted]*

- March 18-19 (Due to ongoing litigation, this meeting is cancelled)
- June 24-26 (Due to ongoing litigation, this meeting is cancelled)
- October 21-23

National Vaccine Advisory Committee (NVAC)

<https://www.hhs.gov/programs/national-vaccine-program/nvac/index.html>

Upcoming Meetings/Latest Updates

No new meeting dates posted.

Solicitation of Nominations for Membership on the National Vaccine Advisory Committee

[Due 12 Sep 2026]

A Notice by the Health and Human Services Department on 08/12/2026

SUMMARY:

The Office of the Assistant Secretary for Health (OASH) is seeking nominations for membership on the National Vaccine Advisory Committee (referred to as NVAC and/or the Committee). The NVAC is a federal advisory committee within the U. S. Department of Health

and Human Services (HHS). Management support for the activities of this Committee is the responsibility of the Office of the Assistant Secretary for Health (OASH). The qualified individuals will be nominated by the Assistant Secretary for Health (ASH) of the U.S. Department of Health and Human Services for appointment to the NVAC. The ASH serves as Director of the National Vaccine Program (NVP).

Members of the Committee, including the Chair, are appointed by the ASH. Members are invited to serve for overlapping terms of up to four years. The NVAC was established to provide advice and make recommendations to the Director of the NVP on matters related to the Program's responsibilities. The functions of the Committee are solely advisory in nature. A copy of the NVAC charter that describes its structure and functions can be reviewed on the NVAC website at: <https://www.hhs.gov/vaccines/nvac/charter/index.html>.

DATES:

Nominations for membership on the NVAC must be received no later than thirty days from publication. Packages received after this time will not be considered for the current membership cycle. <https://www.federalregister.gov/documents/2026/08/12/2026-16399/solicitation-of-nominations-for-membership-on-the-national-vaccine-advisory-committee>

Advisory Commission on Childhood Vaccines (ACCV)

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

Next ACCV meetings – TBD

[Recharter for the Advisory Commission on Childhood Vaccines](#)

A Notice by the Health Resources and Services Administration on 07/21/2026

SUMMARY:

In accordance with the Federal Advisory Committee Act (FACA), the Department of Health and Human Services is hereby giving notice that the Advisory Commission on Childhood Vaccines (ACCV) has been rechartered. The effective date of the renewed charter is July 21, 2026. ... A copy of the ACCV charter is available on the ACCV website at <https://www.hrsa.gov/advisory-committees/vaccines/index.html>.

MMWR Weekly

<https://www.cdc.gov/mmwr/index2026.html>

September 3, 2026 / No. 34

[PDF of this issue](#)

:: [Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2025](#)

.....

National Science Foundation/NSF

[News](#)

No new digest content identified.

.....

U.S. Congress

House

No new digest content identified.

Senate

No new digest content identified.

.....

Supreme Court, Federal & Appellate Courts

O'Neill Institute – Health Care Litigation Tracker [Georgetown University]

<https://litigationtracker.law.georgetown.edu/>

No new digest content identified.

.....
.....
.....

U.S. Medical, Scientific, Professional Societies; Health Organizations

This inventory is evolving and may not capture all instances of relevant comment and analysis.

American Academy of Family Physicians (AAFP)

<https://www.aafp.org/news/media-center.html>

(Accessed 05 Sep 2026)

[AAFP Announces Fall Immunization Recommendations to Protect Patients and Communities](#)

September 2, 2026

Leawood, KS — The American Academy of Family Physicians (AAFP) joins our colleagues across the health care community in encouraging patients of all ages to receive recommended vaccines to keep themselves, their loved ones and their communities healthy. Today, the AAFP released its fall immunization recommendations, in coordination with the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists and the Infectious Diseases Society of America, as part of the Vaccine Integrity Project. The recommendations provide physicians and patients with clear, evidence-based guidance on COVID-19, respiratory syncytial virus (RSV) and influenza vaccines, and are intended to help family physicians ensure patients have access to the immunizations that will best protect their health during respiratory virus season.

"Vaccines are one of medicine's greatest success stories. They prevent serious illness, reduce hospitalizations and long-term complications and save lives," said AAFP President Sarah Nosal, MD, FAAFP. "As federal guidance evolves, the science behind vaccines remains strong. These recommendations are grounded in the latest evidence, informed by public health experts and shaped by what family physicians are seeing every day in their patients."...

American Academy of Pediatrics (AAP)

<https://www.aap.org/en/news-room/news-releases-from-the-aap/>

(Accessed 05 Sep 2026)

News

[American Academy of Pediatrics Issues Recommendations for RSV Immunizations 2026-2027](#)

September 2, 2026

Evidence points to benefits for expanded groups of high-risk children as they enter their second season of RSV

ITASCA, IL—New guidance from the American Academy of Pediatrics expands the categories of high-risk children eligible for immunization against respiratory syncytial virus (RSV), a leading cause of hospitalization among young children.

The AAP continues to recommend RSV immunization for all infants under 8 months of age born during or entering their first RSV season, unless the infant has documented protection from vaccination of their pregnant parent. The AAP expands the high-risk criteria for administration of RSV immunization

in infants and children ages 8 months-19 months entering their second RSV season, as well, according to AAP.

"The evidence is clear: these products work very well to prevent RSV and keep infants out of the hospital," said Sean T. O'Leary, MD, MPH, FAAP, who chairs the RSV immunization subgroup of the AAP Committee on Infectious Diseases. "We're already seeing real-world impact."

The policy statement, "Recommendations for the Prevention of RSV Disease in Infants and Children," will be published in the November 2026 *Pediatrics* (published online at 6 a.m. CT Sept. 2). The AAP will also publish a policy statement, "Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026-2027" on the same day.

All policy statements are [written by medical experts](#), reflect the latest evidence in the field, and undergo several rounds of peer review before being approved by the AAP Board of Directors. and published in *Pediatrics*...

American College of Physicians (ACP)

<https://www.acponline.org/more-acp-news>

(Accessed 05 Sep 2026)

No new digest content identified.

America's Health Insurance Plans (AHIP)

<https://www.ahip.org/news>

(Accessed 05 Sep 2026)

News

No new digest content identified.

American Geriatrics Society (AGS)

<https://www.americangeriatrics.org/media-center>

(Accessed 05 Sep 2026)

Recent Press Releases

No new digest content identified.

American Medical Association (AMA)

<https://www.ama-assn.org/press-center>

(Accessed 05 Sep 2026)

Press Releases

[**AMA, Vaccine Integrity Project unveil independent vaccine evidence review**](#)

Sep 2, 2026 · 4 MIN READ

PDF: [Summary of Vaccine Integrity Project's evidence reviews](#)

MINNEAPOLIS, Minn. — **The Vaccine Integrity Project, in collaboration with the American Medical Association (AMA), today announced the completion of an independent, vaccine evidence review that assessed the safety and effectiveness of immunizations against influenza, SARS CoV-2 and respiratory syncytial virus (RSV).**

The latest high-quality scientific evidence found that these immunizations continue to provide meaningful protection against severe illness, hospitalization and death. Led by the Vaccine Integrity Project, the review also examined new safety data collected since summer 2025 and identified no new safety concerns in comparative studies with currently recommended immunizations.

Based on the most recent peer-reviewed data, the review gives the public the information they need to help inform their vaccination decisions about the three leading causes of serious respiratory virus-related illness.

JAMA published the evidence reviews for RSV, influenza and SARS CoV-2 today. An interactive tool on the Vaccine Integrity Project website lets clinicians, researchers and the public search the studies evaluated by virus or by population group, with links to each paper.

The evidence review helped inform the 2026-27 respiratory virus immunization recommendations released today by the American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), American College of Obstetricians and Gynecologists (ACOG) and Infectious Diseases Society of America (IDSA).

"Immunization continues to be one of our best tools for preventing severe illness from respiratory viruses," Vaccine Integrity Project Executive Director Michael T. Osterholm, PhD, MPH, said. "This year's review confirms that the newest evidence remains consistent with research showing these immunizations reduce the risk of hospitalization and death among the people most likely to experience serious disease."

The AMA and the Vaccine Integrity Project collaborated on the 2026–2027 respiratory virus season evidence review process. The organizations worked with medical specialty societies and public health organizations to identify key policy questions, evaluate emerging evidence to inform immunization recommendations, and to communicate findings to clinicians and patients.

The AMA also launched a digital resource hub with immunization materials for clinicians and patients based on the evidence review and the medical societies' recommendations. The resources reflect an AMA needs assessment of physicians, patients and parents of caregivers, public health professionals, and payers, which identified the tools needed to put this season's vaccine recommendations to practice. These resources, along with the immunization evidence reviews and recommendations, can be found at SpreadTheFacts.org.

"The American public deserves clear, credible information – based on the best available scientific evidence – when making decisions about vaccination. The latest evidence reviews and recommendations are the result of our shared commitment across clinical medicine, science and public health to ensure vaccine recommendations are grounded in sound evidence and developed through a transparent process," said AMA President-elect Sandra Adamson Fryhofer, MD. "We will continue to work together to make sure the public has evidence-based vaccine guidance to help them make informed decisions."

The Vaccine Integrity Project reviewed hundreds of peer-reviewed studies published since August 2025, building on its 2025-26 evidence review of vaccine effectiveness, safety and disease epidemiology data. Prior to 2025, CDC's Advisory Committee on Immunization Practices (ACIP) routinely reviewed vaccine data to guide immunization recommendations. That process was disrupted last year when the U.S. Department of Health and Human Services abruptly dismissed ACIP's members and appointed replacements. Despite a successful court challenge in March, an expert-led ACIP has yet to be restored.

American Osteopathic Association (AOA)

<https://osteopathic.org/news/>

(Accessed 05 Sep 2026)

Latest News

No new digest content identified.

American Public Health Association (APHA)

[https://www.apha.org/news-and-media/news-](https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc)

[releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc](https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc)

(Accessed 05 Sep 2026)

No new digest content identified.

Infectious Diseases Society of America (IDSA)

<https://www.idsociety.org/>

(Accessed 05 Sep 2026)

News

Threats to infectious diseases research leave our country at significant risk

Last Updated September 03, 2026

IDSA and HIVMA are concerned by a notice released Aug. 28 by the National Institutes of Health announcing a proposed overhaul of the National Institute of Allergy and Infectious Diseases' clinical research program with few details and a brief comment period. Changes of the magnitude suggested deserve a lengthier and meaningful opportunity for input from researchers, clinicians, community partners and other stakeholders including Congress.

The proposed restructuring comes after many months of delays in NIH issuing renewal notices for NIAID's clinical trial networks and Centers for AIDS Research, whose discoveries helped establish the United States as a leader in biomedical research worldwide. The renewal notices for the ID networks were finally released this week, but ongoing delays in the renewals for the pioneering CFARs and HIV clinical trial networks are alarming.

Destabilizing NIAID's HIV research infrastructure will harm study participants and further compromise our country's infectious diseases response at a time when ID workforce shortages are worsening and front-line public health systems are eroding due to funding cuts and staffing shortages.

The expertise and stability of NIAID's HIV research networks and centers have fueled discoveries that have saved millions of lives by preventing and treating HIV and other infectious diseases, including viral hepatitis and tuberculosis. These advances include:

Developing HIV antiretrovirals that suppress the deadly virus to undetectable levels and are 99% effective at preventing HIV acquisition

[Laying the groundwork for a cure for hepatitis C Identifying shorter treatment regimens for TB — the deadliest infectious disease worldwide]

We call on NIH to prioritize the health and biosecurity of Americans by immediately releasing the HIV clinical research networks and centers notices of funding opportunities, providing extensions where needed to protect study participants and ensure research in clinical trials underway is not lost. We also urge Congress to conduct the oversight necessary to prevent the dismantling of decades of investments in our nation's biomedical research infrastructure.

— Ronald G. Nahass, MD, MHCM, FIDSA — President, IDSA

— Anna K. Person, MD, FIDSA — Chair, HIVMA

National Foundation for Infectious Diseases (NFID)

<https://www.nfid.org/news-updates/>

(Accessed 05 Sep 2026)

News and Updates

No new digest content identified.

National Medical Association (NMA)

<https://nmanet.org/blog/>

(Accessed 05 Sep 2026)

Latest News

No new digest content identified.

Pediatric Infectious Diseases Society (PIDS)

<https://pids.org/news-announcements/>

(Accessed 05 Sep 2026)

News & Announcements

No new digest content identified.

Society for Healthcare Epidemiology of America (SHEA)

<https://shea-online.org/news/>

(Accessed 05 Sep 2026)

No new digest content identified.

Society for Maternal-Fetal Medicine (SMFM)

<https://www.smfm.org/>

(Accessed 05 Sep 2026)

News

No new digest content identified.

.....
.....

Civil Society – Individuals, Organizations, Institutions [Selected]

.....

Kaiser Family Foundation/KFF [05 Sep 2026]

https://www.kff.org/search/?post_type=press-release

Research, Analysis

No new digest content identified.

.....

Vaccine Integrity Project – CIDRAP [to 05 Sep 2026]

<https://www.cidrap.umn.edu/vaccine-integrity-project>

Announcements, Viewpoints

[Vaccine Integrity Project, American Medical Association review COVID, flu, and RSV vaccines](#)

September 2, 2026 Meghan Holohan

[See AMA release above]

[COMMENTARY: When the federal vaccine process falters, good science cannot stop](#)

September 2, 2026 Michael Osterholm

For more than 60 years, Americans benefited from a federal process designed to answer an extraordinarily important question: What does the best available scientific evidence tell us about how immunizations can be used to protect us from viruses that can hospitalize and even kill?

At the center of that process were the Centers for Disease Control and Prevention (CDC) and its Advisory Committee on Immunization Practices (ACIP). At its best, ACIP brought together leading experts, supported by career CDC scientists, to systematically examine vaccine safety, effectiveness, and disease epidemiology. Its deliberations took place in public, and its recommendations provided physicians and patients with a common source of evidence-based guidance. It was a perpetual machine, (typically) quietly—but vitally—chugging along in the background, while the rest of us went about our daily lives.

Today, that system is no longer functioning.

The federal vaccine-recommendation process is in disarray—to put it mildly—but influenza, COVID-19, and respiratory syncytial virus (RSV) have not stopped circulating. We cannot allow this breakdown to create a vacuum in evidence-based vaccine guidance.

Physicians still have patients to care for. Parents still must make decisions for their children. Older Americans, during pregnancy, and people with underlying health conditions still need reliable information about how best to protect themselves from respiratory viruses.

A thorough review months in the making

That is why the Vaccine Integrity Project at the University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP), working with the American Medical Association (AMA), began preparing back in February for the 2026-27 respiratory virus season.

We collaborated with medical specialty societies and public health organizations to identify the questions clinicians need to answer. As we did last year, our researchers then systematically reviewed the newest scientific evidence on influenza, COVID-19, and RSV immunizations, examining effectiveness and safety and assessing the quality and potential bias of the data.

Those reviews were published in the *Journal of the American Medical Association* and made available to the public, and a tool on the [Vaccine Integrity Project's website](#) lets you look at every study our researchers reviewed and see the evidence for yourself.

Our work builds on last year's effort to ensure that changes in federal vaccine policy do not prevent clinicians and Americans from having access to rigorous, current assessments of vaccine evidence.

Tools for doctors and patients

But an evidence review alone is not enough.

Evidence must be translated into clinical recommendations that physicians and the public health community can use. That is why the work being done by the nation's leading medical specialty societies and the AMA is so important.

This year, the American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and Infectious Diseases Society of America worked together to coordinate the release of their recommendations.

And the AMA has created an online resource center—www.spreadthefacts.org—where clinicians and public health professionals can find information and tools about influenza, COVID-19, and RSV immunization.

Asking key questions, rigorously examining the data

This collaboration is not an attempt to create a rival government vaccine system. I hope it does not need to become one.

The United States needs a strong federal vaccine-recommendation process. We need CDC scientists with deep expertise in infectious diseases, epidemiology and vaccine safety. We need independent experts examining evidence in public. And we need a system insulated from political interference, regardless of which party controls the White House.

Until that system is restored, however, the medical and scientific communities have a responsibility to act.

Americans are understandably asking whom they should trust when they hear conflicting messages about vaccines. I would suggest looking beyond the name of the institutions delivering the message and asking how they reached their conclusion.

Was the evidence systematically reviewed? Were qualified experts involved? Were benefits and risks both examined? Were the methods transparent? Can the public see the evidence supporting the recommendations?

Those questions matter because science is not a matter of institutional authority. It is a process for determining what the evidence tells us—and changing our conclusions when the evidence changes. Americans are understandably asking whom they should trust when they hear conflicting messages about vaccines.

The Vaccine Integrity Project evaluates that evidence. Medical societies independently determine what it means for clinical practice. Physicians then help patients decide what is appropriate for them. That separation of responsibilities is intentional. Our role is not to defend vaccines or reach predetermined conclusions. It is to ask important questions, rigorously examine the evidence and report what we find.

At a moment when much of the national conversation about vaccines has become political, what has happened this year offers a different model. Scientists, physicians, public health experts and medical organizations recognized a gap and worked together to fill it.

Whatever happens next in Washington, one principle should endure: Americans deserve vaccine recommendations grounded in the best available science. We must not lower that standard. Our health and the health of our communities depend on it.

Dr. Osterholm is executive director of the Vaccine Integrity Project and director of CIDRAP.

.....

Center for Vaccine Ethics & Policy - GE2P2 Global Foundation [to 05 Sep 2026]

<https://centerforvaccineethicsandpolicy.net/>

No new digest content identified.

.....

Paul Offit, MD – *Beyond the Noise*

Substack: <https://pauloffit.substack.com/>

No new digest content identified.

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Organization Announcements

Paul G. Allen Frontiers Group [05 Sep 2026]

<https://alleninstitute.org/news-press/>

AI BioDesign accelerator combines experimental biology and artificial intelligence to learn nature's design rules

Researchers from the Allen Institute, University of Washington, and Fred Hutch Cancer Center, supported by Fund for Science and Technology, will build open AI models, datasets, and tools to accelerate biological design for health, sustainability, and other global challenges

September 3, 2026

Gates Foundation [05 Sep 2026]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

No new digest content identified.

CARB-X [05 Sep 2026]

<https://carb-x.org/>

News

No new digest content identified..

Chan Zuckerberg Initiative [05 Sep 2026]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [05 Sep 2026]

<http://cepi.net/>

News

CEPI

Indonesia steps up Southeast Asia's outbreak preparedness with pandemic simulation exercise

Over 120 experts working across the vaccine and epidemic preparedness research ecosystem in Indonesia and the region are taking part in the table-top event in Jakarta.

2 Sept 2026

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 05 Sep 2026]

<https://cioms.ch/>

News; Publications; Events

Reciprocal Effects of Drugs & the Microbiome – 2nd webinar

Online - October 7, 2026 Webinar Time: 14:00 – 15:30 (UTC+2, CEST)

DARPA – Defense Advanced Research Projects Agency [U.S.] [05 Sep 2026]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases Initiative [05 Sep 2026]

<https://dndi.org/press/press-releases/>

Press Releases

No new digest content identified.

Duke Global Health Innovation Center [05 Sep 2026]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [05 Sep 2026]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [05 Sep 2026]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [05 Sep 2026]

<http://www.euvaccine.eu/>

News

[Prof. Umberto D'Alessandro joins EVI as Medical Director](#)

EVI warmly welcomes Prof. D'Alessandro to the team and looks forward to working with him in advancing the organisation's mission

Fondation Merieux [05 Sep 2026]

<http://www.fondation-merieux.org/>

Actualités

No new digest content identified.

Gates Medical Research Institute [05 Sep 2026]

<https://www.gatesmri.org/news>

News: Articles and Publications

No new digest content identified.

Gavi [to 05 Sep 2026]

<https://www.gavi.org/>

News Releases, VaccinesWork

2 September 2026

Global initiative launched to improve access to mpox vaccines

GE2P2 Global Foundation [05 Sep 2026]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements/Digests

:: **Vaccines and Global Health: The Week in Review** - Current edition

:: **Public Consultations Watch :: Global Calls for Input/Public Comment – 04 Sep 2026 Issue 43**

GHIT Fund [05 Sep 2026]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 05 Sep 2026]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [05 Sep 2026]

<https://www.glopid-r.org/>

News & Event

No new digest content identified.

Hilleman Laboratories [05 Sep 2026]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [05 Sep 2026]

<https://www.hhmi.org/news>

News & Stories

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [05 Sep 2026]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [05 Sep 2026]

<https://www.iavi.org/>

Press Releases, Features

No new digest content identified.

INSERM [05 Sep 2026]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 05 Sep 2026]

<https://www.ich.org/page/public-consultations>

News/Pubs/Press Releases [Selected]

2 September 2026

[ICH and ISoP Sign MOU to Advance Global Awareness and Adoption of Harmonised Pharmacovigilance Requirements](#)

ICH and ISoP have signed a Memorandum of Understanding to formalise their strategic collaboration to strengthen global awareness, recognition and adoption of ICH Guidelines, with a focus on pharmacovigilance, medication safety and MedDRA, a standardised international medical terminology produced by ICH.

1 September 2026

[MedDRA Version 29.1 released in English](#)

MedDRA Version 29.1 was released today in English. All 26 language translations will be available on 15 September 2026.

ICRC [to 05 Sep 2026]

<https://www.icrc.org/en/news>

Latest press releases and statements

No new digest content identified.

IFFIm [05 Sep 2026]

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 05 Sep 2026]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press releases

[Global initiative launched to improve access to mpox vaccines](#)

02/09/2026 | *Press release*

IPPS - International Pandemic Preparedness Secretariat [05 Sep 2026]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [05 Sep 2026]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

InterAcademy Partnership (IAP)

<https://www.interacademies.org/news/press-releases>

News

Mon, 31 August 2026

[Antonella di Trapani appointed IAP Coordinator](#)

The IAP has appointed Dr Antonella di Trapani as its new Coordinator. She will join the IAP Trieste Secretariat on 1 September 2026.

ISC / International Science Council [to 05 Sep 2026]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News, Blogs

blog

03 September 2026 - 5 min read

[Bridging science and governance in Latin America and the Caribbean](#)

The ISC RFP-LAC, along with CEPAL, is working together to strengthen legislative science advice and anticipatory governance.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News, Resources

No new digest content identified.

IVAC [05 Sep 2026]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [05 Sep 2026]

<http://www.ivl.int/>

IVI News & Announcements

[IVI and Karolinska Institutet sign Memorandum of Understanding to strengthen existing cooperation in vaccine research and education](#)

[IVI marks 25 years of its International Vaccinology Course with global training connecting Seoul, Kigali, and Stockholm](#)

[IVI and Malaysia's MOSTI commemorate Malaysia's accession to IVI](#)

Johns Hopkins Center for Health Security [05 Sep 2026]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

Robert Wood Johnson Foundation [to 05 Sep 2026]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

Latest News and Highlights

No new digest content identified.

MSF/Médecins Sans Frontières [to 05 Sep 2026]

<http://www.msf.org/>

Latest [Selected Announcements]

Kiribati

[Water security and public health in a changing climate](#)

Project Update 4 Sep 2026

Colombia

[Urgent needs persist three weeks after earthquake in Colombia](#)

Project Update 2 Sep 2026

Conflict in Sudan

[Bringing water and healthcare to displaced people in Abu Jubayhah, South Kordofan](#)

Project Update 1 Sep 2026

National Academy of Medicine - USA [to 05 Sep 2026]

<https://nam.edu/programs/>

News, Stories, Insights

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM] - USA [to 05 Sep 2026]

<https://www.nationalacademies.org/newsroom>

News

No new digest content identified.

PATH [05 Sep 2026]

<https://www.path.org/media-center/>

Newsroom [Selected]

New SARS-CoV-1 antibody available for vaccine researchers

September 3, 2026 by PATH

Targeted antibodies can speed the development and testing of vaccines globally.

A collaboration between PATH, Baylor College of Medicine, and the Medicines and Healthcare products Regulatory Agency (MHRA) has made a monoclonal antibody (mAb) specific for SARS-CoV-1 available to researchers globally. This mAb can support the development of vaccines for SARS-CoV-1 and its evolving variants, as well as future characterization of novel and multivalent coronavirus vaccines.

Rockefeller Foundation [to 05 Sep 2026]

<https://www.rockefellerfoundation.org/>

News and Announcements

No new digest content identified.

Sabin Vaccine Institute [05 Sep 2026]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [05 Sep 2026]

<http://www.unaids.org/en>

News, Stories, Updates

Press Statement

UNAIDS condemns the destruction of lifesaving HIV supplies in Ukraine

04 Sep 2026

UNAIDS strongly condemns the destruction of a warehouse containing HIV supplies in the region of Kyiv. The warehouse, which was destroyed on 19 July, was used by Ukraine's National HIV Prevention Programme to store HIV prevention supplies for programmes reaching more than 300,000 people each year...

UNICEF [to 05 Sep 2026]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

Press release 04 September 2026

Flight lands in Kathmandu carrying vital humanitarian supplies for children and families affected by Nepal floods

KATHMANDU, 4 September 2026, – A flight carrying 84 metric tonnes of critical humanitarian supplies landed in Kathmandu, Nepal this morning, with the support of the European Union Humanitarian Aid. UNICEF is dispatching the supplies to bring urgently needed assistance for children and families affected by the dev...

Press release 03 September 2026

More than one week on from Nepal's floods, thousands of children remain without safe water and face rising risk of disease

KATHMANDU, 3 September 2026, – More than one week after flash floods swept down the Bhotekoshi-Trishuli river basin in Nepal, at least 22,000 children urgently need safe drinking water, sanitation, and hygiene support, UNICEF said today. Water supply systems have been damaged across the affected districts, from co...

Press release 02 September 2026

Global initiative launched to improve access to mpox vaccines

GENEVA/NEW YORK/COPENHAGEN, 2 September 2026 – , A global initiative to establish a stockpile of mpox vaccines was launched on 27 August, creating a long-term mechanism to ensure countries have access to vaccines when responding to mpox outbreaks. Set to begin operations later this month, this new global mpox vac...

Remarks 01 September 2026

UNICEF Executive Director Catherine Russell opening remarks at the second regular session of the 2026 UNICEF Executive Board

NEW YORK, 1 September 2026 –, “Excellencies, distinguished delegates, colleagues ... welcome to the second regular session of the UNICEF Executive Board for 2026. “Thank you to the President and to the Bureau for your continued leadership. “We meet today at a consequential moment for children, for UNICEF, and for th...

Unitaid [05 Sep 2026]

<https://unitaid.org/>

News releases

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [05 Sep 2026]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified. [Last update Jun 30, 2023]

Vaccine Confidence Project [05 Sep 2026]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [05 Sep 2026]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update Newsletter August 2026

Wellcome Trust [05 Sep 2026]

<https://wellcome.org/>

News. Opinion, Reports

No new digest announcements identified.

The Wistar Institute [to 05 Sep 2026]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest announcements identified.

World Bank [to 05 Sep 2026]

<http://www.worldbank.org/en/news/all>

News [Selected]

No new digest announcements identified.

WFPHA: World Federation of Public Health Associations [05 Sep 2026]

<https://www.wfpha.org/>

Blog, Events

Protecting Every Child from Severe Respiratory Disease Through Immunization

Sep 2, 2026

Preventing death and disease from Respiratory Syncytial Virus (RSV) and Pneumococcal Disease in all our children RSV and pneumococcal disease are longstanding threats to child health, but we are at a turning point: after decades of research, we now...

World Medical Association [WMA] [to 06 Sep 025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest announcements identified.

World Organisation for Animal Health [WOAH/OIE] [05 Sep 2026]

<https://www.oie.int/>

Latest News

No new digest announcements identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [05 Sep 2026]

<https://alliancerm.org/press-releases/>

Selected Press Releases

Press Releases

ARM Names Suzy Jacobs Chief Operating Officer

BIO [05 Sep 2026]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [05 Sep 2026]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

EFPIA – European Federation of Pharmaceutical Industries and Associations

<https://www.efpia.eu/news-events/>

News & Events

Statements & press releases 01.09.26

Europe recognised life sciences as a strategic priority. The MFF must now make Europe the place to invest

Europe's capacity to discover, develop and manufacture medical innovation is central to its competitiveness, health security and resilience. The next Multiannual Financial Framework (MFF) should therefore translate the ambitions of the Competitiveness Compass, the Life Sciences Strategy, including the Biotech Act, into sustained investment across the full innovation journey, from excellent science to clinical development, regulatory readiness, manufacturing, deployment and patient access...

ICBA – International Council of Biotechnology Associations [05 Sep 2026]

<https://internationalbiotech.org/>

News

No new digest announcements identified.

IFPMA [05 Sep 2026]

<https://ifpma.org/>

News & Resources

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [05 Sep 2026]

<https://www.iapo.org.uk/news>

Press and media [Selected]

AMATA Statement at the 76th WHO Regional Committee for Africa

Tuesday, 1 September 2026

Agenda item 11: Regional strategy on regulation of medical products in the African Region, 2026–2035

The members of the African Medicines Agency Treaty Alliance (AMATA) welcome and strongly support the adoption of the Regional Strategy on Regulation of Medical Products in the African Region, 2026–2035.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [05 Sep 2026]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....

.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News - No new digest announcements identified.

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified.

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified....

CanSinoBIO

News - Website not responding at inquiry.

CIGB

Latest News - Website not responding at inquiry.

CinnaGen – Iran

CinnaGen News - Website not responding at inquiry.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

CSL Seqirus

News Releases - No new digest announcements identified.

Curevac

News - Website now directs to BioNTech site

Dailchi Sankyo

Press Releases - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

01 Sep 2026

[GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data](#)

:: Results showed higher immune responses versus standard and high dose flu vaccines in younger and older adults respectively¹

:: Vaccine candidate designed to target the two primary surface antigens that cause flu viruses to bind and spread
:: Phase III trial to start in September 2026

EuBiologics, S Korea

News - No new digest announcements identified.

HIPRA

Press releases - No new digest announcements identified.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified

Moderna

News and Blog Posts - No new digest announcements identified

Nanogen

News - No new digest announcements identified.

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Samsung Biologics

Latest News - No new digest announcements identified

Sanofi Pasteur

Press Releases - No new digest announcements identified.

Serum Institute

News & Announcements - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 17 2026 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 12: E823-875 December 2025

<https://journalofethics.ama-assn.org/issue/aging-bad-you>

Aging Is Bad for You?

At some point along life's trajectory, growing becomes aging. Gerotherapeutics—biologically-based approaches to health that target processes of aging—seem poised to respond. This theme issue investigates ethical valences of what gerotherapeutics suggest about our socially, culturally, and historically entrenched patterns of pathologizing and medicalizing aging. Advancement in our understanding of physiological mechanisms of aging has prompted some to reconceive lifespans as

health spans. Geroscience also suggests the need to critically evaluate whether and to what extent we should think of anti-aging ventures as legitimate enterprises of health care. Normative roles played by aging in our personal and relational narratives, in our expectations about how duration and quality of life confer value to life, and in how life extension promotes or undermines our notions of wisdom and a good life are all at stake.

American Journal of Human Genetics

Aug 06, 2026 Volume 113 Issue 8 p1583-1778

<https://www.cell.com/ajhg/current>

This month in *The Journal*

Paul W. Hook, Alyson B. Barnes

Whereas cis-acting regulatory variants are located near their target genes and affect regions such as promoters and enhancers, trans-acting regulatory variants can be located anywhere in the genome and affect expression through a variety of indirect mechanisms. Trans-eQTLs contribute a sizable fraction of gene expression variation, but identifying these variants continues to pose challenges. Indeed, it is thought that mismapping of sequencing reads could lead to spurious results, suggesting the need to revisit the known catalog of trans-eQTLs for mismapping artifacts.

American Journal of Infection Control

August 2026 Volume 54 Issue 8 p829-930

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

August 2026 Volume 71 Issue 2

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

August 2026 116(8)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 115 (2026): Issue 2 (Aug 2026)

<https://www.ajtmh.org/view/journals/tpmd/115/2/tpmd.115.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

August 2026 Volume 179, Issue 8

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 358 September 2026

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/358/suppl/C>
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 05 Sep 2026)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 05 Sep 2026)

[Springer-Nature site down at inquiry]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 05 Sep 2026)

[Springer-Nature site down at inquiry]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 05 Sep 2026)

[Springer-Nature site down at inquiry]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 05 Sep 2026)

[Springer-Nature site down at inquiry]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 05 Sep 2026)

[Springer-Nature site down at inquiry]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 05 Sep 2026)

["I didn't even know humans could get polio ... I swear that's for dogs." A co-produced, thematic analysis exploring adolescent attitudes to vaccines](#)

Angie Pitt, Richard Amlôt, Louise E. Smith

Research Open access 05 September 2026

[Factors associated with influenza vaccination uptake among adults with self-reported respiratory diseases in Hungary: a cross-sectional study](#)

Gergő Hegyes, Jenifer Pataki, Gergő József Szöllősi

Research Open access 03 September 2026

Barriers and facilitators of seasonal influenza vaccinations in German and Chinese health care workers - a comparative cross-sectional study

Linda Sanftenberg, Yiqing Weng, Jochen Gensichen
Research Open access 01 September 2026 Article: 2501

Sentiments and themes in the public posts related to influenza vaccines in China: Insights from Weibo data in 2023

Jiaxin Zhang, Desheng Huang, Fan Li
Research Open access 31 August 2026

Trust, information quality, adverse events following immunization, and social influences as determinants of vaccination decisions: a cross-sectional study

Dorota Stefanicka – Wojtas, Agnieszka Rusiecka, Donata Kurpas
Research Open access 31 August 2026

Physicians' role in recommending Human Papillomavirus Vaccination—a qualitative study in the context of national immunization rollout

Muneer Ahmed, Azra Batool, Matti Ullah
Research Open access 31 August 2026

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 05 Sep 2026)

[Springer-Nature site down at inquiry]

BMJ Evidence-Based Medicine

August 2026 - Volume 31 - 4

<https://ebm.bmj.com/content/31/4>

[Reviewed earlier]

BMJ Global Health

August 2026 - Volume 11 - 8

<https://gh.bmj.com/content/11/8>

[Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - July 2026

<https://thebulletin.org/magazine/2026-05/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 104, Number 8, August 2026, 525-584

<https://www.who.int/publications/journals/bulletin>

[Reviewed earlier]

Cell

Aug 06, 2026 Volume 189 Issue 16 p4825-5150

<https://www.cell.com/cell/current>

[Reviewed earlier]

Cell and Gene Therapy Insights

February 2026 Issue, Volume 12 Issue 1

<https://www.insights.bio/cell-and-gene-therapy-insights/journal/283/volume-12-issue-1>

[Reviewed earlier]

Child Care, Health and Development

Volume 52, Issue 5 September 2026

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 120, Issue 2 Pages: 289-562 August 2026

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

August 2026 Volume 48 Issue 8 p677-808

<http://www.clinicaltherapeutics.com/current>

Special Issue on "Advancing Diversity, Racial Equity & Inclusion in Clinical Research - Part II"

[Reviewed earlier]

Clinical Trials

Volume 23 Issue 4, August 2026

<https://journals.sagepub.com/toc/CTJ/current>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 05 Sep 2026]

[Springer-Nature site down at inquiry]

Contemporary Clinical Trials

Volume 167 August 2026

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/167/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 9 Issue 4, August 2026

<https://journals.sagepub.com/toc/tcja/9/4>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 14, Issue 1 December 2026

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 42, Issue 6, 2026

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

August 2026 - Volume 39 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 05 Sep 2026]

[No new digest content identified]

Cytotherapy

September 2026 Volume 28 Issue 9

<https://www.isct-cytotherapy.org/current>

[Reviewed earlier]

Developing World Bioethics

Volume 26, Issue 2 Pages: 81-130 June 2026

<https://onlinelibrary.wiley.com/toc/14718847/current>

Special Issue: Military Global Health Engagements

[Reviewed earlier]

Development in Practice

Volume 36, 2026 Issue 4

<https://www.tandfonline.com/toc/cdip20/36/4?nav=tocList>

[Reviewed earlier]

Development Policy Review

Volume 44, Issue 5 September 2026

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 20 - 2026

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 50, Issue 4 October 2026

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

eBioMedicine

Volume 130 August 2026

<https://www.sciencedirect.com/journal/ebiomedicine/vol/130/suppl/C>

Research article Open access

[COVID-19 vaccination timing, relative to acute COVID-19, and subsequent risk of long COVID](#)

Zachary Butzin-Dozier, Yunwen Ji, Lin-Chiun Wang, A. Jerrod Anzalone, ... Xiaohan Tanner Zhang
Article 106382

EMBO Reports

Volume 27, Issue 16 August 2026

<https://link.springer.com/journal/44319/volumes-and-issues/27-16>

[New issue; No digest content identified]

Emerging Infectious Diseases

Volume 32, Number 9—September 2026

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

Epidemics

Volume 55 June 2026

<https://www.sciencedirect.com/journal/epidemics/vol/55/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 154 - 2026

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 48, Issue 4 Pages: 1-45 July–August 2026

<https://onlinelibrary.wiley.com/toc/25782363/current>

Organ-on-a-chip technology :: Consent and decisional incapacity

[Reviewed earlier]

Ethics & International Affairs

Volume 40 - Issue 1 - Spring 2026

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 33 2025

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/33/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 36, Issue 3, June 2026

<https://academic.oup.com/eurpub/issue/36/3>

[Reviewed earlier]

Expert Review of Vaccines

Volume 25, 2026 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

September/October 2026 Volume 105, Number 5

<https://www.foreignaffairs.com/issues/2026/105/5>

[Reviewed earlier]

Forum for Development Studies

Volume 53, 2026 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[New issue: No digest content identified]

Frontiers in Genetics

<https://www.frontiersin.org/journals/genetics>

[Accessed 05 Sep 2026]

Review Accepted on 02 Sep 2026

[Artificial Intelligence for Precision Gene Therapy: Emerging Technologies, Clinical Applications, and Future Directions](#)

Govinder Flora, Abhinay Thakur

Abstract

Artificial Intelligence (AI) is revolutionizing gene therapy from an empirical and iterative process to a predictive, data-driven and increasingly intelligent therapeutic development approach. This review covers the application of AI extensively throughout the gene therapy development process, from target therapeutic discovery, identification of disease genes, variant interpretation, integration of multi-omics

data, optimization of CRISPR, engineering of the vector, prediction of immunogenicity, manufacturing, and clinical development and post-marketing surveillance. The role of machine learning, deep learning, foundation models, generative AI and digital twins for advancing therapeutic design, boosting vector performance, manufacturing optimization, patient stratification and enabling precision medicine is discussed. Lastly, we provide directions for future research and highlight the need for close multidisciplinary cooperation between computational scientists, biologists, clinicians, industry, and regulatory agencies to facilitate the development of safe, effective and personalized genetic medicines responsibly.

Frontiers in Genome Editing

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 05 Sep 2026]

[No new digest content identified]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 05 Sep 2026]

Review Accepted on 04 Sep 2026

[**Vaccination of patients with hematological malignancies: barriers and strategies to improve uptake**](#)

Toni Valković, Paolo Salamon, Vanja Vasiljev, Tomislav Rukavina

Gene Therapy – Nature

Volume 33 Issue 4, July 2026

<https://www.nature.com/gt/volumes/33/issues/4>

[Reviewed earlier]

Genetics in Medicines

Volume 28, Issue 8 August 2026

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/28/issue/8>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 05 Sep 2026]

[No new digest content identified]

Global Health Action

Volume 19, Issue 1 (2026)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

August 2026

<https://pmc.ncbi.nlm.nih.gov/search/?term=%22Glob%20Health%20Sci%20Pract%22%5Bjournal%5D>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 05 Sep 2026]

[No new digest content identified]

Global Public Health

Volume 21, Issue 1 (2026)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 05 Sep 2026]

[Springer-Nature site down at inquiry]

Health and Human Rights

Volume 28, Issue 2, June 2026

<https://www.hhrjournal.org/volume-28-issue-1-june-2026/>

Special Section: Children's Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 21 - Issue 3 - July 2026

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 41, Issue 7, August 2026

<https://academic.oup.com/heapol/issue/41/7>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 05 Sep 2026]

[Springer-Nature site down at inquiry]

Human Gene Therapy

Volume 37 Issue 13-14, July 2026

<https://journals.sagepub.com/toc/hgta/37/13-14>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

[Accessed 05 Sep 2026]

[No new digest content identified]

Immunity

Jul 14, 2026 Volume 59 Issue 7 p1777-2054

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 05 Sep 2026]

[Springer-Nature site down at inquiry]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

Latest articles

[Springer-Nature site down at inquiry]

International Health

Volume 18, Issue 4, July 2026

<https://academic.oup.com/inthealth/issue/18/4>

[Reviewed earlier]

International Human Rights Law Review

Volume 15 (2026): Issue 1 (Jun 2026)

<https://brill.com/view/journals/hrlr/hrlr-overview.xml>

[Reviewed earlier]

The International Journal of Children's Rights

Volume 34 (2026): Issue 2 (Jun 2026)

<https://brill.com/view/journals/chil/34/2/chil.34.issue-2.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 13 No. 8 (2026): August 2026

<https://www.ijcmph.com/index.php/ijcmph/issue/view/139>

Articles

[New issue; No digest content identified]

International Journal of Epidemiology

Volume 55, Issue 3, June 2026

<https://academic.oup.com/ije/issue/55/3>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 19, Issue 2 22 April 2026

<https://www.emerald.com/ijhrh/issue/19/2>

[Reviewed earlier]

JAMA

September 1, 2026, Vol 336, No. 9, Pages 721-810

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Health Forum

August 2026, Vol 7, No. 8

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

August 2026, Vol 180, No. 8, Pages 811-920

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JB1 Evidence Synthesis

August 2026 - Volume 24 - Issue 8

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

September 2026 Volume 79 Issue 3 p293-450

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 85 (2026)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 51, Issue 4 August 2026

<https://link.springer.com/journal/10900/volumes-and-issues/51-4>

[Reviewed earlier]

Journal of Development Economics

Volume 183 September 2026

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/183/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 21 Issue 3, July 2026

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

June 2026 - Volume 80 - 6

<https://jech.bmj.com/content/80/6>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 19, Issue 2 June 2026

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 22, Issue 1 (2026)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 37, Number 3, August 2026

<https://muse.jhu.edu/issue/56931>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 28, Issue 4 August 2026

<https://link.springer.com/journal/10903/volumes-and-issues/28-4>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 24, Issue 3 (2026)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 38, Issue 5 Pages: 773-931 July 2026
<https://onlinelibrary.wiley.com/toc/10991328/current>
[Reviewed earlier]

Journal of Law, Medicine & Ethics

Volume 54 - Supplement S2 - Summer 2026
<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>
Supported Decision-Making in Clinical Research
[Reviewed earlier]

Journal of Medical Ethics

August 2026 - Volume 52 - 8
<http://jme.bmj.com/content/current>
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 13, Issue 2 (2026)
<https://institutionalrepository.aah.org/jpcrr/>
[Reviewed earlier]

The Journal of Pediatrics

Volume 294 July 2026
<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/294/suppl/C>
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 19, 2026 Issue 1
<https://www.tandfonline.com/toc/jppp20/19/1?nav=tocList>
[Reviewed earlier]

Journal of Public Health Management & Practice

September/October 2026 - Volume 32 - Issue 5
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>
[Reviewed earlier]

Journal of Public Health Policy

Volume 47, Issue 2 June 2026
<https://link.springer.com/journal/41271/volumes-and-issues/47-2>
[Reviewed earlier]

Journal of the Royal Society – Interface

Volume 23, Issue 242 1 September 2026
<https://royalsocietypublishing.org/toc/rsif/current>
[New issue; No digest content identified]

Journal of Travel Medicine

Volume 33, Issue 5, July 2026

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

The Lancet

Sep 05, 2026 Volume 408 Number 10558 p867-968, e4-e9

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

Offline: How to save WHO

Richard Horton

I am optimistic about the future for WHO. Still, despite the passionate protestations of the agency's current Director-General (DG), Tedros Adhanom Ghebreyesus—namely, that the need for a strong WHO has never been greater—the reality is that the world's only intergovernmental health institution is at its weakest moment since the nadir of 1998. At that time, Hiroshi Nakajima bequeathed an agency in crisis, badly mishandling the global response to an emerging AIDS pandemic and widely mistrusted by countries after allegations of electoral corruption. As now, the prospects for WHO seemed bleak. Recognising that moment of peril, the Rockefeller Foundation convened a series of gatherings to identify preconditions for the agency's renewal. Their work contributed to the election of Norway's former Prime Minister, Gro Harlem Brundtland. Thanks to the respect she commanded among fellow political leaders, together with her deft administrative skills, Brundtland restored WHO's standing and confidence, launched critically important new health programmes, and delivered real successes for global health, such as the WHO Framework Convention on Tobacco Control. Today, WHO finds itself at a similar turning point, wounded financially and reputationally by the sudden withdrawal of the USA. Instead of focusing its stretched resources on health programmes, the agency's leadership has been forced to devote much of its time to unprecedented downsizing. Inevitably, WHO has found it hard to reclaim its voice.

What of the future? Four candidates have declared themselves (the deadline for country nominations is Sept 24): Hans Kluge, WHO's Regional Director for Europe; Hanan Balkhy, WHO's Regional Director for the Eastern Mediterranean; Hanan Al-Kuwari, Qatar's former Minister of Public Health; and Budi Gunadi Sadikin, Indonesia's current Minister of Health. There are whispers about possible late entrants. Of the four, Sadikin is the outsider. A former banker, he became Minister of Health in 2020. He is promoting his track record in managing Indonesia's COVID-19 response and his efforts to digitally transform access to health care across his country. Balkhy, a paediatrician and infectious disease specialist, has led her region since 2024. She was a former WHO Assistant Director-General for Antimicrobial Resistance. Al-Kuwari was a government minister from 2016 to 2024. She was educated in health-care management and led Qatar's largest health provider. Kluge is the first candidate to publish his election manifesto. He explicitly acknowledges that WHO is facing difficulties. His manifesto is entitled, *Rebuilding the World Health Organization Together*. He calls himself WHO's "most candid critic".

I did not know Nakajima. But I have known and, in some cases, worked with his successors—Brundtland (1998–2003), J-W Lee (2003–06), Anders Nordström (2006–07), Margaret Chan (2007–17), and Tedros (2017–27). I am neither a political scientist nor an insightful psephologist. But it strikes me that there are some pointers to what makes a more or less successful DG. First, political experience. The higher the level in government a prospective DG has served, the better. Brundtland proved that if you want to influence presidents and prime ministers, it is important they see you as their equal. Second, appoint people smarter than yourself to senior roles and give them the freedom and authority to lead. Again, Brundtland is the best example: David Heymann, Julio Frenk, Derek Yach. Third, keep member states close and use their influence. A DG who can call on a committed political leader to front

up a campaign, commission, or initiative will amplify their impact and bring in other leaders. Fourth, persuade the UN Secretary-General (UNSG) to take health more seriously. When Ban Ki-moon (UNSG 2007–16) made women's and children's health one of his signature initiatives, he transformed a health sector issue into a global political movement. He drew in leaders such as Stephen Harper (Canada), Jakaya Kikwete (Tanzania), and Jens Stoltenberg (Norway). Finally, many observers will say that being a good communicator is an essential attribute. Yes and no. A basic ability to communicate your ideas is important. But good communication without robust, meaningful, and inspiring content becomes empty rhetoric. The best DGs have launched original and transformational health programmes, often triggered through partnerships with the academic medical and global health communities. So, should you be optimistic about the future of WHO? You have to be. There is no other choice.

Comment Online first September 03, 2026

[Closing the preparedness gap: moving beyond emergency response to sustain the medical countermeasure ecosystem](#)

Victor J Dzau [Send email to victor.dzau@duke.edu](mailto:victor.dzau@duke.edu) · Jean Kaseyab · Benedict Oramahc · John-Arne Røttingend · Jane Haltone · Elizabeth E Cameronf · et al.

The Lancet Child & Adolescent Health

Aug 2026 Volume 10 Number 8 p541-612, e23
<https://www.thelancet.com/journals/lanchi/issue/current>
[Reviewed earlier]

Lancet Digital Health

Jul 2026 Volume 8 Number 7
<https://www.thelancet.com/journals/landig/issue/current>
[Reviewed earlier]

Lancet Global Health

Sep 2026 Volume 14 Number 9
<https://www.thelancet.com/journals/langlo/issue/current>
Articles

[Global feasibility of cervical cancer elimination: a multidimensional scenario-based modelling analysis across 175 countries](#)

Mauricio A Cuello, Fernán Gomez-Valenzuela, Ignacio Wichmann, Alexander B Olawaiye

Review

[The 2025 small island developing states report of the Lancet Countdown on health and climate change: building resilience in the face of rising heat](#)

Georgiana M Gordon-Strachan, et al.

Viewpoint

[Global health ethics in international collaborative research during policy transition: what can we learn from the proposed newborn hepatitis B vaccine trial in Guinea-Bissau?](#)

Keymanthri Moodley, Stuart Rennie, Brian D Earp

Summary

International collaborative research in Africa has raised ethical challenges for decades. The proposed newborn hepatitis B vaccine trial in Guinea-Bissau is the latest case to crystallise concerns around potential exploitation of disadvantaged populations, drawing comparisons to Tuskegee and other research abuses. We argue that the decision to stop the trial was appropriate, but that the reasons

most invoked in public debate are incomplete. The trial was designed to happen during a defined window before Guinea-Bissau's planned rollout of the universal birth-dose vaccination in 2027–28, when randomisation between the WHO-recommended birth dose and the existing local standard of care remained possible. Under what conditions, if any, could such research—comparing a local versus global standard of care during health policy transition—be ethically justified? We propose four conditions and assess the proposed trial against them. The trial potentially satisfies some of our proposed conditions but does not meet others owing to an absence of maternal hepatitis B screening despite high background prevalence, methodological shortcomings that threaten the interpretability of results, and governance deficiencies, including an absence of sponsor-country ethics review (required by the Declaration of Helsinki). We treat this trial as a cautionary tale offering important lessons for future research in low-resource settings undergoing policy transitions.

Lancet Infectious Diseases

Aug 2026 Volume 26 Number 8 p751-870, e268-e320
<https://www.thelancet.com/journals/laninf/issue/current>
[Reviewed earlier]

Lancet Public Health

Aug 2026 Volume 11 Number 8 e472-e582
<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

Aug 2026 Volume 14 Number 8 p647-746, e51-e56
<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 30, Issue 8 August 2026
<https://link.springer.com/journal/10995/volumes-and-issues/30-8>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 46 Issue 6, August 2026
<https://journals.sagepub.com/toc/MDM/current>
[Reviewed earlier]

Medical Law International

Volume 26 Issue 3, September 2026
<https://journals.sagepub.com/toc/MLI/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 104, Issue 2 Pages: 293-580 June 2026

<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Aug 05, 2026 Volume 34 Issue 8 p4339-5020
<https://www.cell.com/molecular-therapy/current>
[Reviewed earlier]

Nature

Volume 657 Issue 8130, 3 September 2026
<https://www.nature.com/nature/volumes/655/issues/8130>
World View 28 Aug 2026

[The Moderna cancer vaccine offers hope — now we must speed up personalized therapies](#)

A positive trial holds promise for treating people with cancer. More research is needed to get effective vaccines to the clinic.

Patrick A. Ott

Nature Biotechnology

Volume 44 Issue 7, July 2026
<https://www.nature.com/nbt/volumes/44/issues/7>
[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>
(Accessed 05 Sep 2026)
[Reviewed earlier]

Nature Genetics

Volume 58 Issue 8, August 2026
<https://www.nature.com/ng/volumes/58/issues/8>
Comment 07 Jul 2026

[Toward a framework for measuring the impact of ELSI research](#)

Despite growing investment in research addressing the ethical, legal and social implications (ELSI) of genomics, the field lacks frameworks for measuring the impact of ELSI on policy, governance and institutional practice. This Comment highlights why existing metrics fail to capture the distinctive contributions of ELSI and proposes four interconnected steps toward a systematic assessment.

Diya Uberoi, Dianne Nicol

Nature Human Behaviour

Volume 10 Issue 7, July 2026
<https://www.nature.com/nathumbehav/volumes/10/issues/7>
[Reviewed earlier]

Nature Medicine

Volume 32 Issue 8, August 2026

<https://www.nature.com/nm/volumes/32/issues/8>

Comment 06 Jul 2026

Data rights are the missing pillar for modernizing consent in medicine

Nada S. Salem

Nature Reviews Drug Discovery

Volume 25 Issue 8, August 2026

<https://www.nature.com/nrd/volumes/25/issues/8>

[Reviewed earlier]

Nature Reviews Genetics

Volume 27 Issue 8, August 2026

<https://www.nature.com/nrg/volumes/27/issues/8>

[Reviewed earlier]

Nature Reviews Immunology

Volume 26 Issue 8, August 2026

<https://www.nature.com/nri/volumes/26/issues/8>

[Reviewed earlier]

New England Journal of Medicine

Volume 395 No. 9 September 3, 2026

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 5 No. 6 June 2026

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

npj Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 05 Sep 2026]

[Reviewed earlier]

Pediatrics

Volume 158, Issue 2 August 2026

<https://publications.aap.org/pediatrics/issue/158/2>

[Reviewed earlier]

PharmacoEconomics

Volume 44, Issue 8 August 2026

<https://link.springer.com/journal/40273/volumes-and-issues/44-8>
[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>
(Accessed 05 Sep 2026)

The 100 Diatom Genomes Project

Thomas Mock, Gust Bilcke, Elliott Flaum, Shunan Fu, Lilian Hoch, Kevin Moog, Nadine Rijsdijk, Elizabeth C. Ruck, Ian W. Bishop, Carole Duchene, Reuben Gilbertson, Amanda Hopes, Christopher Johns, Francesco Manfellotto, Wade R. Roberts, Nigel Belshaw, Udit Chandola, Peter Chaerle, Olga Chepurnova, Daan Deleu, Sofie D'hondt, Federica Di Costanzo, Omayya Dudin, Serena Flori, Trupti Gaikwad, Agnes Groisillier, Andrea Hall, Pengyu Ji, Louis J. Lavier-Aydat, William H. Lewis, Samuel Menicot, Eveline Pinseel, Eléonore Pottier, Krisztina Sarkozi, Arianna Smerilli, Jan Strauss, Sander Thierens, Andrew Toseland, Yousef Touhami, Robert Utting, Michiel Van Bel, Cock van Oosterhout, Yue Wu, Feng Yang, Erika Allhusen, John J. Bolton, Chris Bowler, Thorsten Brinkhoff, Anja Poehlein, Tim Brovarone, Nansheng Chen, Greg Clark, Matthew D. Clark, Dario Copetti, Zongmei Cui, Beini Deng, Jianbo Jian, Uwe John, Anne D. Jungblut, JiHeon Kang, Jon Bent Kristoffersen, JunMo Lee, Shuya Liu, David G. Mann, Linda Medlin, Vincent Moulton, Jelena Radojicic, Shinya Sato, Rosa Trobajo, Klara Wolf, Norico Yamada, Naihao Ye, Libin Zhang, Yunyun Zhuang, Gautam Dey, Valeria Di Dato, Katherine Helliwell, Marianne Jaubert, Peter G. Kroth, Marina Montresor, Giovanna Romano, Tatiana A. Rynearson, Jayson Talag, Klaus U. Valentin, Flora Vincent, Ross F. Waller, Glen Wheeler, Andrew J. Alverson, Kerrie Barry, LoriBeth Boston, Angela Falciatore, Maria Immacolata Ferrante, Jie Guo, Jane Grimwood, Richard Hayes, Andrei Herdean, Jerry Jenkins, Min Kim, Wiebe HCF Kooistra, Alan Kuo, Anna Lipzen, Nicole Poulsen, Jeremy Schmutz, Leïla Tirichine, Klaas Vandepoele, Frédéric Verret, Wim Vyverman, Igor V. Grigoriev

Community Page | published 01 Sep 2026 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3003947>

One hundred diatom species have been selected for genome and transcriptome sequencing. The 100 Diatom Genomes Project aims to provide a scalable framework for understanding diatom biodiversity, ecology and evolution, and for investigating their use in biotechnology

PLoS Genetics

<https://journals.plos.org/plosgenetics/>
(Accessed 05 Sep 2026)
[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSglobalPublicHealth&q=&resultsPerPage=60
(Accessed 05 Sep 2026)

Ensuring children's inclusion in the Bundibugyo Ebola response: Striving to do better this time

Mike Kalmus Elias, Michael Adeyemi-Lawal, Lauren D'Mello Guyett, Daniela Manno, Bruce Myango, Paula Reges, Neal Russell

Opinion | published 02 Sep 2026 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0007117>

Nearly one in five essential medicines fail quality standards in Africa: A systematic review and meta-analysis of MNCH medicines and antimalarials

Jean Christophe Rusatira, Manuela Dorado Novoa, Jean Berchmans Uwimana, Cameron Persaud, Eishita Pal, Ayesha Khan, Henry Michtalik, Neelaveni Padayachee, Murray Lumpkin, Charles Preston, Saifuddin Ahmed

Research Article | published 02 Sep 2026 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0006326>

PLOS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 05 Sep 2026)

[No new digest content identified]

PLOS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 05 Sep 2026)

[No new digest content identified]

PLOS One

<http://www.plosone.org/>

[Accessed 05 Sep 2026]

[Human papillomavirus \(HPV\) and HPV vaccine awareness in Indigenous communities in Northwest Territories, Canada](#)

Afsaneh Omidimorad, Fariba Kolahdooz, Ghazal Kolahdooz, Adrian Wagg, Paul Veugelers, André Corriveau, Kami Kandola, Stephanie Irlbacher-Fox, Gina Ogilvie, Carolyn Gotay, Sangita Sharma

Research Article | published 03 Sep 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0357586>

[Effectiveness of monitoring mechanisms in reducing immunization dropouts among infants in health facilities of Maridi County, South Sudan](#)

Daniel Opinile Mark Igga, Nzomo Mwita, Kennedy Muni

Research Article | published 03 Sep 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0356268>

PLOS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 05 Sep 2026]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

September 1, 2026 | vol. 123 | no. 35

<https://www.pnas.org/toc/pnas/123/35>

[New issue; No digest content identified]

PNAS Nexus

Volume 5, Issue 7, July 2026

<https://academic.oup.com/pnasnexus/issue/5/7>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 41 - Issue 1 - 2026

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 210 September 2026

<https://www.sciencedirect.com/journal/preventive-medicine/vol/210/suppl/C>

[New issue; No digest content identified]

Proceedings of the Royal Society B

Volume 293, Issue 2077 August 2026

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 257 August 2026

<https://www.sciencedirect.com/journal/public-health/vol/257/suppl/C>

Editorial No access

[Disparities in global response to public health emergencies: A tale of two pathogens](#)

Danielle Solomon, Andrew C.K. Lee

Article 106431

Review article Abstract only

[Global determinants of dengue vaccine acceptance: An updated systematic review and meta-analysis](#)

Diego Arriaga-Izabal, Francisco Morales-Lazcano, Uriel A. Angulo-Zamudio, Adrian Canizalez-Román, Nidia León-Sicairos

Article 106350

Research article Abstract only

[Janani Suraksha Yojana's legacy: Determinants of child immunization in Bodoland](#)

Shrabanti Maity

Article 106330

Research article Abstract only

[Perceptions of HPV vaccination among children aged 9-13 and parents: A qualitative study from Ankara, Türkiye](#)

E. Ozeller, H. Sarıca Çevik, L. Peremans

Article 106378

Public Health Ethics

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2026, Vol. 29, No. 1

<https://karger.com/phg/issue/29/1>

[Reviewed earlier]

Public Health Reports

Volume 141 Issue 3, May/June 2026

<https://journals.sagepub.com/toc/phrg/141/3>

[Reviewed earlier]

Qualitative Health Research

Volume 36 Issue 9, August 2026

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 22 Issue 3, July 2026

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 05 Sep 2026]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

[No new digest content identified]

Risk Analysis

Volume 46, Issue 7 July 2026

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 05 Sep 2026]

[No new digest content identified]

Royal Society Open Science

Volume 13, Issue 8 1 August 2026

<https://royalsocietypublishing.org/toc/rsos/current>
[Reviewed earlier]

Science

Volume 393| Issue 6815| 3 Sep 2026
<https://www.science.org/toc/science/current>
[New issue; No digest content identified]

Science and Engineering Ethics

Volume 32, Issue 4 August 2026
<https://link.springer.com/journal/11948/volumes-and-issues/32-4>
[Reviewed earlier]

Science Translational Medicine

Volume 18| Issue 865| 2 Sep 2026
<https://www.science.org/toc/stm/current>
[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>
[Accessed 05 Sep 2026]
[No new digest content identified]

Social Science & Medicine

Volume 405 September 2026
<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/405/suppl/C>
[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>
[Accessed 05 Sep 2026]
[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 47, Issue 4 August 2026
<https://link.springer.com/journal/11017/volumes-and-issues/47-4>
[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 72 July–August 2026
<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/72/suppl/C>
[Reviewed earlier]

Tropical Medicine & International Health

Volume 31, Issue 9 Pages: 1137-1290 September 2026

<https://onlinelibrary.wiley.com/toc/13653156/current>

SCOPING REVIEW

Returned but Not Restored: Experiences of Health and Access to Care Among Return Migrants in Sub-Saharan Africa—A Scoping Review

Sif Sofie Vange, Gershim Asiki, Ama de-Graft Aikins, Charles Agyemang, Eshetu Girma, Ernestina Korleki Dankyi, Marie Norredam

Pages: 1141-1153

First Published: 11 June 2026

Vaccine

Volume 90 17 September 2026

<https://www.sciencedirect.com/journal/vaccine/vol/90/suppl/C>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 05 Sep 2026]

Article

Guidelines on Immunization of People with Chronic Neurological Disorders: A Systematic Review

Giuseppina Lo Moro, et al.

Vaccines 2026, 14(9), 777; <https://doi.org/10.3390/vaccines14090777> (registering DOI)

4 September 2026

Background: People with chronic neurological disorders may be vulnerable to severe outcomes from vaccine-preventable infections. However, immunization recommendations for these patients may be difficult to identify and apply. This systematic review a..

Review

An Analysis of Multilevel Barriers to Human Papillomavirus Vaccination Uptake Among Rural U.S. Adolescents

Tajauna Batchelor, et al.

Vaccines 2026, 14(9), 772; <https://doi.org/10.3390/vaccines14090772>

1 September 2026

Despite longstanding vaccine availability, human papillomavirus (HPV) remains the most common sexually transmitted infection in the United States and a leading cause of preventable cancers. Additionally, HPV vaccination rates remain below other routi..

Review

Maternal Immunization Against Respiratory Syncytial Virus: An Updated WAIID Consensus Document on Evidence, Implementation, and Public Health Priorities

Susanna Esposito, et al.

Vaccines 2026, 14(9), 768; <https://doi.org/10.3390/vaccines14090768>

1 September 2026

Background: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease and hospitalization in early infancy. The availability of maternal RSVpreF vaccination and long-acting infant monoclonal antibodies has created two effe...

Article

The African Polio Laboratory Network: Advancing Regional Poliovirus Detection, Genomic Surveillance, and Eradication

Brook Tesfaye, et al.

Vaccines 2026, 14(9), 766;<https://doi.org/10.3390/vaccines14090766>

1 September 2026

Background: Sustaining progress toward polio eradication requires not only effective vaccination but also a resilient laboratory network capable of timely poliovirus detection, confirmation, and genetic characterization. In the WHO African region, th...

Systematic Review

Knowledge, Attitudes, and Perceptions of HPV Vaccination for Adolescents with Intellectual Disabilities: A Systematic Review

Giuseppina Lo Moro, et al.

Vaccines 2026, 14(9), 764;<https://doi.org/10.3390/vaccines14090764>

31 August 2026

Background/Objectives: Adolescents with intellectual disabilities may experience inequities in preventive healthcare, including HPV vaccination. This review aimed to synthesize evidence on HPV vaccination-related knowledge, attitudes and perceptions...

Systematic Review

Serological Protection After Routine Measles-Containing Vaccination Among Children Aged 1–5 Years in Low- and Middle-Income Countries: A Systematic Review

Imtiaz Hussain, et al.

Vaccines 2026, 14(9), 760;<https://doi.org/10.3390/vaccines14090760>

30 August 2026

Background: Measles remains a major cause of morbidity and mortality among children in low- and middle-income countries (LMICs), despite widespread implementation of routine two-dose measles-containing vaccine (MCV) schedules. Serological assessment...

Review

Advancing Chikungunya Prevention and Vaccination in Mexico: A Position Paper by the Immunization Committee of the Mexican Association of Pediatric Infectious Diseases

Jorge A. Vázquez-Narváez, et al.

Vaccines 2026, 14(9), 756;<https://doi.org/10.3390/vaccines14090756>

29 August 2026

Background: Chikungunya virus (CHIKV) is a mosquito-borne alphavirus transmitted predominantly by *Aedes aegypti* and *Aedes albopictus*. Infection is characterized by an acute febrile illness accompanied by debilitating polyarthralgia, myalgia, and cuta...

Value in Health

August 2026 Volume 29 Issue 8 p1329-1538

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Medical Journal – Official Journal of The World Medical Association

Nr. 4, December 2025, vol. 71

<https://www.wma.net/publications/world-medical-journal/>

[Reviewed earlier]

World Development

Volume 205 September 2026

<https://www.sciencedirect.com/journal/world-development/vol/205/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Pre-Print Servers

arXiv

<https://arxiv.org/>

[Accessed 05 Sep 2026]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

No new digest content identified.

New - bioRxiv

<https://www.biorxiv.org/content/early/recent>

[Accessed 05 Sep 2026]

[Filters: Bioengineering, Evolutionary Biology, Genetics, Genomics, Neuroscience, Synthetic Biology]
Website not fully responding at inquiry...timing out from sequential citation exploration...exploring workaround options]

No new digest content identified.

medRxiv

<https://www.medrxiv.org/content/early/recent>

[Accessed 05 Sep 2026]

[Filter: All articles]

Website not fully responding at inquiry...timing out from sequential citation exploration...exploring workaround options]

[Antimicrobial resistance genomics across Africa: critical determinants, repository bias and regional coordination](#)

Ruth Omani, Grace Njoki Maina, Folorunso Oludayo Fasina

medRxiv 2026.08.31.26361859; doi: <https://doi.org/10.64898/2026.08.31.26361859>

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 05 Sep 2026]

[Filter: All articles]

Research Article metrics

[A mark and recapture perspective on vaccination touchpoints](#)

Niket Thakkar

Funder: Bill and Melinda Gates Foundation

PUBLISHED 01 Sep 2026

Abstract

This paper considers large-scale vaccination campaigns, a major platform for vaccine access in a lot of the world, as a recapture estimate of the target population marked by routine immunization. Framing the campaign as a measurement, we learn about its properties, including the campaign's coverage of the target population and some implied sampling properties of post-campaign coverage surveys (PCCSs), the current gold-standard in implementation quality measurement.

We develop this idea in the context of the 2023 measles campaign in Kano State, Nigeria, where we have detailed implementation data collected by vaccination teams involved in that effort. Looking specifically at the teams' tally sheets, the daily records of who they vaccinated, we find significant discrepancies between the recapture estimates and those from the corresponding PCCS. Exploring a variety of bias models applied to both the tally sheets and the PCCS helps clarify how anecdotal issues from the field relate to this discrepancy.

Overall, we find that the tally sheets, despite being an unorthodox population sample, provide a tractable perspective on implementation and measurement, one that's in principle available nearly instantly and at high resolution for any vaccination touchpoint.

Research Article metrics

[Leave no one behind: Global Analysis on monitoring childhood vaccination timeliness and catch-up using data from the WHO/UNICEF joint reporting form on Immunization](#)

M. Carolina Danovaro-Holliday, Ignacio Castro-Aguirre, Mitsuki Koh, Inae Carolyn Kim, Yoann Nedelec, Marcela Contreras, Naor Bar-Zeev, Martha Velandia-Gonzalez, Marta Gacic-Dobo

Funders: Gates Foundation,

GAVI Alliance

PUBLISHED 01 Sep 2026

Abstract

In the years following the Covid-19 pandemic, immunization programmes have increasingly focused on the capacity to conduct and monitor catch-up vaccination—for doses administered later than the recommended schedule. However, it is unclear whether information systems are able to monitor delayed vaccination. We analyzed WHO/UNICEF Joint Reporting Form data from 194 countries (2016–2022) to understand if systems for tracking delayed childhood vaccination are available and quantify catch-up doses of the first dose of a measles-containing vaccine (MCV1). For Latin American and Caribbean countries, we also explored data for the third dose of diphtheria-tetanus-pertussis vaccine (DTP3).

We assessed the completeness and consistency of reporting, the proportion of delayed doses, and vaccination coverage considering both timely and delayed administration. Analyses were disaggregated by WHO Region, World Bank income classification, and Gavi support eligibility.

Results show substantial variability across regions and income groups in countries' ability to capture delayed doses. Between 2016 and 2022, the proportion of countries reporting a system to record delayed doses ranged from 55.5% to 64.4% annually, with the Region of the Americas (AMR) consistently reporting a higher proportion (77.1%–82.9%). Among countries with available data, the median proportion of delayed MCV1 doses was 4.4%, suggesting that including catch-up doses in cohort monitoring would increase reported coverage by approximately 4 percentage points. This increase was smaller in Gavi-eligible countries compared with non-eligible countries.

The study summarizes global differences in information systems to monitor catch-up vaccination, presents examples of cohort coverage monitoring and illustrates the need to further improve

immunization information systems and explore the potential for improving vaccination coverage and population immunity through catch-up activities.

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

No new digest content identified.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 05 Sep 2026]

No new digest content identified.

* * * *

Think Tanks

Brookings [to 05 Sep 2026]

<http://www.brookings.edu/>

Research, Events

No new digest content identified.

Center for Global Development [05 Sep 2026]

<https://www.cgdev.org/>

All Research

CGD NOTE

AI RCTs Are Booming—To Be Useful, They Must Evolve

Tim Ohlenburg et al.

August 27, 2026

AI RCTs are on the rise, a trend that's set to continue, and is likely to intensify. But randomising a rapidly evolving, increasingly widely adopted, technology poses a distinct set of challenges. So how can we actually garner durable, generalisable and policy relevant insights?

Chatham House [to 05 Sep 2026]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [05 Sep 2026]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 05 Sep 2026]

<https://www.csis.org/>

Reports [Selected]
No new digest content identified.

IS Global [to 05 Sep 2026]
<https://www.isglobal.org/en/press>
Newsroom
No new digest content identified.

McKinsey Global Institute [to 05 Sep 2026]
<https://www.mckinsey.com/mgi/overview>
Featured Research
No new digest content identified.

ODI [Overseas Development Institute] [to 05 Sep 2026]
<https://odi.org/en/publications/>
Publications
Poverty and public finance: a primer
02 September 2026
Research report

This primer bridges that gap. It gives public finance staff a clear, practical grounding in poverty measurement, then shows how that understanding connects directly to fiscal policy design, tax and transfer analysis, and evidence-based reform.

Pew Research Center [to 05 Sep 2026]
<https://www.pewresearch.org/>
Latest Publications
No new digest content identified.

Rand [to 05 Sep 2026]
<https://www.rand.org/pubs.html>
Published Research [Selected]
Commentary Sep 4, 2026

AI Can Now Design Viruses. We Need Biosecurity Guardrails Now

As AI advances, the risk of engineered viral bioweapons is growing. The window to prepare is now—by building a layered, resilient system of defense.

Expert Insights Sep 2, 2026

Countering Model Distillation: Limits and Alternatives

Artificial intelligence model distillation (training new models on outputs of more capable ones) could affect U.S. frontier model advantage. New policy tools could augment such technical countermeasures as raising costs or reducing model quality.

Sep 2, 2026

A Standardized Framework for Assessing High-Risk Life Sciences Research: Defining Objective Criteria That Can Facilitate Expert and AI Reviews of Dangerous Gain-of-Function Research

Recent federal policies establish funding prohibitions and review requirements for certain high-risk

life sciences research. The authors advise that federal agencies adopt an objective decisionmaking framework for dangerous gain-of-function research.

Commentary Aug 31, 2026

Mirror Life Is Theoretical. The Danger Is Anything But.

With mirror life, scientists have given world leaders both the foresight and the time to address the danger. What's needed isn't alarm but action to ensure that mirror life remains just a footnote in human history—and not its final chapter.

Urban Institute [to 05 Sep 2026]

<https://www.urban.org/research>

New Research Publications - Selected

No new digest content identified.

World Economic Forum [to 05 Sep 2026]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....
.....

Public Consultations/Calls for Inputs/Calls for Papers

Request for Information: Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making

A Notice by the Health and Human Services Department on 08/24/2026, **Comment period ends 09/20/2026.**

SUMMARY:

The Department of Health and Human Services (HHS or the Department), in support of the Task Force on Safer Childhood Vaccines and in furtherance of the Executive Order of August 10, 2026, "Delivering Gold Standard Childhood Vaccine Recommendations for Americans," seeks public comment on whether the categories currently used in Federal vaccine recommendations are adequate. Those categories are routine (universal) recommendations, risk-based recommendations, and recommendations based on shared clinical decision-making, also referred to as individual-based decision-making. The Department seeks comment on these categories and whether additional or different categories should be adopted. The Department further seeks comment on the considerations that should be relied upon in setting vaccine recommendations, including the availability and strength of available scientific evidence, the appropriate approach when randomized controlled trial evidence is limited or absent, a presumption in favor of individual autonomy and religious freedom, the downstream legal and programmatic consequences of category assignment, and the communication practices necessary to earn and maintain public trust.

WMA - Declaration of Taipei Revision Launched [Ongoing]

...The Declaration of Taipei tries to achieve a balance between the rights of individuals giving their tissue or data for research and other purposes based on confidentiality and privacy rules while at the same time recognising that health data has become a very powerful tool for increasing knowledge.

In analysing the scenarios that already exist for the use (and misuse) of health data and biobanks, we came to the conclusion that the major risk scenarios may not result from science, but from the commercial, administrative or political use of such data. Limiting our guidelines to research only would

have left us blind to the imminent risk of abuse from outside the field of medicine: commercialization, cost-cutting and potential political abuse.

Therefore, in contrast to the Declaration of Helsinki, this policy aims to address any use of health databases and biobanks excluding individual treatment and is not restricted to research. As physicians are the primary custodians of confidential health information, they feel an obligation towards their patients and other persons who entrust them with their data and specimens...

In April 2025, the WMA appointed a workgroup to initiate the revision process of this document. To encourage as much global participation in the revision process as possible, the WMA is collaborating with its members to host a series of regional meetings...

* * * *

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2026. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#) and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*